Format

Send to

Choose Destination
See comment in PubMed Commons below
Case Rep Oncol. 2013 Oct 24;6(3):531-7. doi: 10.1159/000356080. eCollection 2013.

Early relapse of unresectable gallbladder cancer after discontinuation of gemcitabine monotherapy administered for 5 years in a patient who had complete response to the treatment.

Author information

1
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan ; Department of Medical Oncology, Toranomon Hospital, Tokyo, Japan.
2
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan.
3
Division of Hepatobiliary and Pancreatic Oncology, National Cancer Center Hospital East, Kashiwa, Japan ; Department of Gastroenterology and Neghrology, Chiba University, Chiba, Japan.
4
Division of Pathology, National Cancer Center Hospital East, Kashiwa, Japan.
5
Hepatobiliary and Pancreatic Oncology Division, National Cancer Center Hospital, Tokyo, Japan.
6
Department of Internal Medicine, Medical Oncology, Kyorin University School of Medicine, Tokyo, Japan.

Abstract

The tumor shrinkage effect of gemcitabine is considered to be limited in cases of advanced gallbladder cancer, and there are few reports of complete response to gemcitabine therapy in patients with this cancer. Therefore, the treatment continuation strategy in these patients, after a complete response has been achieved, still remains to be established. Here, we present the case of a 77-year-old patient with unresectable gallbladder cancer, who after showing complete response to gemcitabine monotherapy administered for 5 years, showed early relapse within only 11 months of discontinuation of the drug. Thus, it is necessary to establish a suitable treatment continuation strategy for patients who show complete response to gemcitabine treatment.

KEYWORDS:

Chemotherapy; Complete response; Early relapse; Gallbladder cancer; Gemcitabine

PubMed Commons home

PubMed Commons

0 comments
How to join PubMed Commons

    Supplemental Content

    Full text links

    Icon for S. Karger AG, Basel, Switzerland Icon for PubMed Central
    Loading ...
    Support Center